Ipsen Polandsp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2005-08-17
Share capital
1,210,000.00 PLN
Average employment (people)
64 (2025)
Activity description

Ipsen Poland operates in the biopharmaceutical industry, focusing on oncology, rare diseases and neuroscience. The company develops medicines for patients with unmet medical needs; products named in the excerpt include Dysport and IQIRVO.

Registered address
ul. Chmielna 69, 00-801 Warszawa, Poland
Website
Phone
Social media
Electronic delivery address
AE:PL-13611-39160-RBEDF-18

Financials

Revenue history (in m)

From the notes

Current income tax (CIT due)$660,709
Profit allocationRetained in reserve capital
Planned capital expenditure (next year)$492,215
Foreign sales15.03% of revenue ($14,131,112)
Revenue structureusługi promocyjne/reklamowe
Receivables write-downs$14,647

Filing timeliness

3 of 6 financial statements were filed late (the longest delay 410 days for 2020). All were audited by a statutory auditor.

  • 202516/07/2026
  • 202430/06/2025
  • 202308/07/2024
  • 202211/07/2023
  • 202129/11/2022
  • 202029/11/2022
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Wholesale of pharmaceutical goods69 / 1,141
Top 6.0%
Division · Wholesale trade331 / 19,988
Top 1.7%
City · Warszawa670 / 56,967
Top 1.2%
Voivodeship · Mazowieckie861 / 77,130
Top 1.1%
Country · Poland2,419 / 297,932
Top <1%

Results vs industry

Revenue
This companyUSD 94.81mMedianUSD 1.07mAverageUSD 22.38m
Net profit
This companyUSD 2.10mMedianUSD 37.89kAverageUSD 879.28k
Operating costs
This companyUSD 91.46mMedianUSD 929.75kAverageUSD 21.06m
Assets
This companyUSD 45.14mMedianUSD 609.81kAverageUSD 11.84m

News

Characterizing the patient experience: The role of patient‑reported outcomes

Characterizing the patient experience: The role of patient‑reported outcomes

Biological endpoints are essential, but on their own, they cannot tell the full story. To truly understand the value of a treatment and care surrounding it, we must also seek to understand how patients and carers experience it. This is where patient-reported outcomes (PROs) and observer‑reported outcomes (reflecting the perspectives of non-clinical caregivers) are becoming more prominent in clinical research.

A bridge to the field: how real-world data informs rare disease care

A bridge to the field: how real-world data informs rare disease care

As a Field Medical Advisor in Rare Disease, Antonios Letis works at the intersection of data, physicians, and patients. His focus includes cholestatic conditions such as PBC — areas where innovation has shifted what is possible.

Rethinking discovery: how powerful screening tools are redefining the search for new medicines

Rethinking discovery: how powerful screening tools are redefining the search for new medicines

In medicine discovery, identifying the right biological target has always been a critical and complex step. Today, the rise of powerful screening tools is fundamentally reshaping this process, creating a step-change in how we move from scientific hypotheses to transformative medicines. Advances in high-throughput screening, genomics and AI-driven analytics are enabling scientists to interrogate disease biology at unprecedented scale, bringing forward opportunities that were previously beyond rea

Adult PFIC: Why Some People Spend Years Searching for Answers

Adult PFIC: Why Some People Spend Years Searching for Answers

PFIC is a group of rare inherited liver conditions that affects the body's ability to transport and circulate bile, which is essential for digesting and absorbing fats, as well as removing waste products.1–5 When bile builds up in the liver , it can damage the liver and cause symptoms such as itching.1

When science advances, understanding must keep pace

When science advances, understanding must keep pace

We are living in an era of extraordinary scientific progress. We can target diseases in ways that were unimaginable a generation ago, develop increasingly sophisticated medicines and explore entirely new approaches to treatment.

Building more sustainable laboratories with My Green Lab

Building more sustainable laboratories with My Green Lab

Science is at the heart of everything we do. It also comes with an environmental footprint, from the energy and water used in laboratories to the chemicals, equipment and materials required to advance our work.

Industry

Offer

  • Oncology medicines
  • Rare disease medicines
  • Neurological medicines
  • Therapies

Website technology

Website
  • WordPress

Authorized Representatives

Gábor Sztaniszláv – Management Board Member
Rafael Giglio – Management Board Member

Manner of representation

Each member of the management board has the right to represent the company independently.

Ownership

OwnerSharesShare valueStake
Ipsen Farmaceutica Bv
198$323,581.8599%
Others
2$3,268.501%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2005-09-02.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 67,096

Public aid

No public aid cases recorded in the last 10 years.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Amgensp. z o.o.
Zentiva Polskasp. z o.o.
Angelini Pharma Polskasp. z o.o.
Stada Pharmsp. z o.o.
Olympus Polskasp. z o.o.
Magnapharm Polandsp. z o.o.
Aurovitas Pharma Polskasp. z o.o.
Kol-Dentalsp. z o.o. + limited partnership
Baxter Polskasp. z o.o.
Galderma Polskasp. z o.o.

Change history

DateEvent
2026-09-09Address change
2021-03-11Address change
2019-06-12PKD change
2015-02-27PKD change
2014-04-07Share capital increase

FAQ

Last updated: 2026-09-09